We selected six candidates related to tumorigenesis, drug-resistance and cancer progression, and discovered that the promoters of GATA4 and ETS1 were occupied with more H3K4me3 modification resulting in enhanced expression of mRNA and protein levels of GATA4 and ETS1 in recurrent tumors and T24 Mut with MLL mutation compared with primary tumors and T24 WT with wild type MLL respectively. This evidence concerns the gene ETS1 and cancer.